ArticleJournal of translational medicine2026
Ion channel gene signature for diagnosis and antifibrotic therapy in liver fibrosis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver fibrosis (LF) is a progressive pathological process that may lead to cirrhosis and liver failure. Human ion channel genes (HICGs) participate in hepatic mechanotransduction and immune regulation, but their contributions to LF remain insufficiently characterized. This study aimed to profile the expression of HICGs in LF and to identify key genes with diagnostic and therapeutic relevance.
methodsMultiple transcriptomic datasets were integrated to identify differentially expressed HICGs in LF. Weighted gene co-expression network analysis and single-cell RNA sequencing were applied to identify fibrosis-associated gene modules and cell-type distribution. Functional enrichment and immune infiltration analyses were performed to explore biological relevance. The expression of key genes was validated in human cirrhotic tissues and bile duct ligation mouse models using immunohistochemistry. Potential therapeutic compounds targeting hub HICGs were predicted through molecular docking simulations.
resultsThree HICGs-AQP1, GJA1, and KCNN2-were identified as fibrosis-associated hub genes, showing distinct expression patterns and high diagnostic performance. GJA1 showed consistent upregulation in both experimental models and human cirrhosis. Functional analyses linked these genes to extracellular matrix remodeling, cell adhesion, and cytokine interactions, while immune infiltration analysis revealed significant associations with M0 macrophages, plasma cells, NK cells, and memory B cells. Molecular docking simulations further identified 16 candidate drugs targeting KCNN2 and GJA1.
conclusionsThis study demonstrates that AQP1, GJA1, and KCNN2 are closely associated with LF progression and immune remodeling. The consistent upregulation of GJA1, together with the identification of candidate drug interactions, provides potential avenues for biomarker development and therapeutic repurposing in LF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.